User profiles for Tyler Hulett

Tyler Hulett

CDI Labs
Verified email at cdi-lab.com
Cited by 376

[HTML][HTML] Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19

…, M Bosticardo, T Kawai, JJ Danielson, T Hulett… - Nature medicine, 2022 - nature.com
Pediatric Coronavirus Disease 2019 (pCOVID-19) is rarely severe; however, a minority of
children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might …

Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC

…, L Lacroix, F Griscelli, G Roman, T Hulett… - Science …, 2023 - science.org
Circulating senescent CD8 + T (T 8 sen) cells are characterized by a lack of proliferative
capacities but retain cytotoxic activity and have been associated to resistance to immunotherapy …

[HTML][HTML] Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts

ZT Wehrmann, TW Hulett, KL Huegel, KT Vaughan… - PLoS …, 2012 - journals.plos.org
Niemann-Pick Type C disease (NPC) is a lethal, autosomal recessive disorder caused by
mutations in the NPC1 and NPC2 cholesterol transport proteins. NPC’s hallmark symptoms …

[HTML][HTML] Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine

DB Page, TW Hulett, TL Hilton, HM Hu, WJ Urba… - … for immunotherapy of …, 2016 - Springer
Because the benefits of immune checkpoint blockade may be restricted to tumors with pre-existing
immune recognition, novel therapies that facilitate de novo immune activation are …

[HTML][HTML] Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination

TW Hulett, SM Jensen, PA Wilmarth, AP Reddy… - … for immunotherapy of …, 2018 - Springer
Background One of today’s greatest hurdles for cancer immunotherapy is the absence of
information regarding which tumor antigens are already recognized by patients receiving …

Multi-omics approach identifies novel age-, time-and treatment-related immunopathological signatures in MIS-C and pediatric COVID-19

…, M Bosticardo, T Kawai, JJ Danielson, T Hulett… - medRxiv, 2021 - medrxiv.org
Pediatric COVID-19 (pCOVID-19) is rarely severe, however a minority of SARS-CoV-2-infected
children may develop MIS-C, a multisystem inflammatory syndrome with significant …

An Efficient Synthesis of (±)-Trichostatic Acid and Analogues: A New Route to (±)-Trichostatin A

A Chatterjee, J Richer, T Hulett, VBR Iska, O Wiest… - Organic …, 2010 - ACS Publications
An efficient synthesis of rac-trichostatic acid (1) and its analogues is reported starting from a
commercially available aldehyde. Further manipulations of rac-1 led to rac-trichostatin A (…

Argonaute, vault, and ribosomal proteins targeted by autoantibodies in systemic lupus erythematosus

…, X Wang, R Najjar, KC Ukadike, S Hu, T Hulett… - The Journal of …, 2023 - jrheum.org
Objective To expand, in an unbiased manner, our knowledge of autoantigens and autoantibodies
in patients with systemic lupus erythematosus (SLE) and evaluate their associations …

[HTML][HTML] Development of a Novel Circulating Autoantibody Biomarker Panel for the Identification of Patients with 'Actionable'Pulmonary Nodules

…, CL Fhied, A Abdelkader, M Vargas, S Hu, T Hulett… - Cancers, 2023 - mdpi.com
Simple Summary Circulating biomarkers for the identification of patients with “actionable”
nodules may increase screening uptake and decrease false-positive rates associated with low-…

Evolution of concise and flexible synthetic strategies for trichostatic acid and the potent histone deacetylase inhibitor trichostatin A

…, J Löfstedt, T Ankner, J Richer, T Hulett… - European Journal of …, 2013 - Wiley Online Library
(R)‐(+)‐Trichostatic acid and (R)‐(+)‐trichostatin A (TSA) are natural products that have
attracted considerable attention in the field of epigenetic therapies. TSA in particular is a …